CC BY
13
«АКТУАЛЬНЫЕ ВОПРОСЫ ИММУНОГЕНЕТИКИ И ТКАНЕВОГО ТИПИРОВАНИЯ»
Санкт-Петербург 24-25 июня 2015 г.
out our historical expanse. Then maternally inherited genetic traits will be explored by mitochondrial DNA analysis to ensure that a maternal counterpart
to the paternal line of descent will be available as a necessary complement to present genetic background of the Armenians.
Naumova E.
Department of Clinical Immunology and Stem Cell Bank, University Hospital «Alexandrovska», Medical University, Sofia, Bulgaria
STRATEGY FOR FINDING THE SUITABLE DONOR IN HSCT
Haematopoietic stem cell transplantation (HSCT) is limited by finding a suitable donor. The »best» donor is HLA matched sibling or unrelated donor. Unfortunately, in most cases the probability to find HLA identical sibling does not exceed 30 % and depends on the family size. Additionally, number of factors restrict the probability to find HLA matched donor in Bone Marrow Donors Worldwide such as patient's ethnicity, presence of rare alleles or haplotypes, possible relevance of «non-classical» HLA and non-HLA alleles. All these factors should be considered for the estimation of time for donor search. For the Bulgarian patients the mean time to identify 10/10 matched donor varies from 28 to more than 90 days depending on the HLA genotype. Patient's related factors such as diagnosis and disease stage and transplant protocol are also important
for donor selection and clinical outcome of HCST. In order to increase the efficacy of transplantation alternative strategies such as umbilical cord blood, mismatched unrelated adult donor or haploidenti-cal related donor are considered for patients lacking HLA identical donor. In such cases it is important to estimate a number of clinically relevant factors, such as: the time for engraftment and haematopoie-sis reconstitution, graft failure rate, graft versus host disease, transplant related mortality and relapses. Current data in the literature as well as our experience on the relevance of immunogenetic factors in HSCT will be discussed. An algorithm for finding the most suitable donor, that could help clinicians to provide an adequate treatment for each individual patient will be presented.
Nezih Cereb, MD
CEO & Co-founder Histogenetics
ADVANCES IN DNA SEQUENCING TECHNOLOGIES FOR HIGH RESOLUTION HLA TYPING
Recent advances in DNA sequencing technologies, so-called Next Generation Sequencing (NGS), have brought breakthroughs in deciphering the genetic information in all living species at a large scale and at an affordable level.
By introducing DNA barcode (index) sequences multiplexing samples from hundreds of individual became possible for genotyping certain genomic regions faster and cheaper with higher resolution.
In this talk I will present Histogenetics's experience and accomplishments in applying NGS for large-scale high resolution HLA typing. Histogenet-
ics had established Sanger capillary technology in 2006 for large volume DNA-based sequencing typing and more than 3.8 million samples were typed with that technique. Histogenetics' existing infrastructure helped us to transition to the NGS technologies without compromising accuracy, volume of typing and speed. In March 2013 Histogenetics introduced a Hybrid approach of Sanger + Illumina MiSeq DNA sequencing. A total 460,190 samples were typed with MiSeq + Sanger to validate MiSeq data during transition to NGS, shown in the table 1.
